Literature DB >> 28887181

Treatment resistant schizophrenia and neurological soft signs may converge on the same pathology: Evidence from explanatory analysis on clinical, psychopathological, and cognitive variables.

Andrea de Bartolomeis1, Emiliano Prinzivalli2, Gemma Callovini2, Luigi D'Ambrosio2, Benedetta Altavilla2, Camilla Avagliano2, Felice Iasevoli2.   

Abstract

Here, we investigated neurological soft signs (NSSs) in treatment resistant schizophrenia (TRS) vs treatment responder schizophrenia (SZ) patients. TRS is a severe condition, affecting approximately one-third of schizophrenia patients and representing a relevant clinical challenge. NSSs are neurological abnormalities reportedly described in schizophrenia patients and linked to dysregulated network connections. We explored the possibility that NSSs may be: i) more severe in TRS patients; ii) differentially associated to clinical/cognitive variables in TRS vs SZ; iii) predictive of having TRS. In addition, we evaluated whether diagnosis may mediate NSSs associations with the above-mentioned variables. Consecutive patients with schizophrenia diagnosis underwent stringent assessment for TRS diagnosis. Demographics and clinical variables were recorded. Psychopathology (by Positive and Negative Syndrome Scale, PANSS), cognitive performances, and NSSs (by Neurological Evaluation Scale, NES) were tested. TRS had higher scores than SZ patients in total NES score and in almost all NES subscales, even after correction for duration of illness and antipsychotic dose (ANCOVA, p<0.05). NSSs significantly correlated with multiple clinical, psychopathological, and cognitive variables (above all: duration of disease and negative symptoms) in TRS but not in SZ patients. Two-way ANOVA showed NSS-x-diagnosis interaction in determining outcomes on multiple cognitive performances, but not in other clinical variables. However, simple main effect analysis detected a significant relationship between high severity NSSs and TRS diagnosis on multiple clinical and cognitive outcomes. Hierarchical regression analysis showed that diagnosis was among a discrete number of predictors yielding significant increases in variance explained on NES total, Sensory Integration and Other Signs subscales' scores. NSSs, together with antipsychotic dose and disease severity, were found to be significantly predictive of TRS diagnosis in a binary logistic regression model. These results suggest a stringent association between NSSs and TRS diagnosis, and may imply that NSSs association with clinical, psychopathological, and cognitive variables may be in part mediated by TRS diagnosis.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28887181     DOI: 10.1016/j.pnpbp.2017.09.002

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  9 in total

1.  Neurological Soft Signs Predict Auditory Verbal Hallucinations in Patients With Schizophrenia.

Authors:  Robert C Wolf; Mahmoud Rashidi; Mike M Schmitgen; Stefan Fritze; Fabio Sambataro; Katharina M Kubera; Dusan Hirjak
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

2.  Disease Severity in Treatment Resistant Schizophrenia Patients Is Mainly Affected by Negative Symptoms, Which Mediate the Effects of Cognitive Dysfunctions and Neurological Soft Signs.

Authors:  Felice Iasevoli; Camilla Avagliano; Benedetta Altavilla; Annarita Barone; Luigi D'Ambrosio; Marta Matrone; Danilo Notar Francesco; Eugenio Razzino; Andrea de Bartolomeis
Journal:  Front Psychiatry       Date:  2018-10-31       Impact factor: 4.157

3.  Severity in sustained attention impairment and clozapine-resistant schizophrenia: a retrospective study.

Authors:  An-Sheng Lin; Hung-Yu Chan; Ying-Chieh Peng; Wei J Chen
Journal:  BMC Psychiatry       Date:  2019-07-12       Impact factor: 3.630

4.  Predictors of treatment resistant schizophrenia: a systematic review of prospective observational studies.

Authors:  S E Smart; A P Kępińska; R M Murray; J H MacCabe
Journal:  Psychol Med       Date:  2019-08-29       Impact factor: 7.723

5.  Analysis of mRNA and Protein Levels of CAP2, DLG1 and ADAM10 Genes in Post-Mortem Brain of Schizophrenia, Parkinson's and Alzheimer's Disease Patients.

Authors:  Anna Di Maio; Arianna De Rosa; Silvia Pelucchi; Martina Garofalo; Benedetta Marciano; Tommaso Nuzzo; Fabrizio Gardoni; Andrea M Isidori; Monica Di Luca; Francesco Errico; Andrea De Bartolomeis; Elena Marcello; Alessandro Usiello
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923

Review 6.  Rational and Translational Implications of D-Amino Acids for Treatment-Resistant Schizophrenia: From Neurobiology to the Clinics.

Authors:  Andrea de Bartolomeis; Licia Vellucci; Mark C Austin; Giuseppe De Simone; Annarita Barone
Journal:  Biomolecules       Date:  2022-06-29

7.  Haplotypic and Genotypic Association of Catechol-O-Methyltransferase rs4680 and rs4818 Polymorphisms and Treatment Resistance in Schizophrenia.

Authors:  Marina Sagud; Lucija Tudor; Suzana Uzun; Matea Nikolac Perkovic; Maja Zivkovic; Marcela Konjevod; Oliver Kozumplik; Bjanka Vuksan Cusa; Dubravka Svob Strac; Iva Rados; Ninoslav Mimica; Alma Mihaljevic Peles; Gordana Nedic Erjavec; Nela Pivac
Journal:  Front Pharmacol       Date:  2018-07-03       Impact factor: 5.810

8.  Patterns of Management of Patients With Dual Disorder (Psychosis) in Italy: A Survey of Psychiatrists and Other Physicians Focusing on Clinical Practice.

Authors:  Massimo Clerici; Andrea de Bartolomeis; Sergio De Filippis; Giuseppe Ducci; Icro Maremmani; Giovanni Martinotti; Fabrizio Schifano
Journal:  Front Psychiatry       Date:  2018-11-13       Impact factor: 4.157

9.  Relationships between early age at onset of psychotic symptoms and treatment resistant schizophrenia.

Authors:  Felice Iasevoli; Eugenio Razzino; Benedetta Altavilla; Camilla Avagliano; Annarita Barone; Mariateresa Ciccarelli; Luigi D'Ambrosio; Marta Matrone; Federica Milandri; Danilo Notar Francesco; Michele Fornaro; Andrea de Bartolomeis
Journal:  Early Interv Psychiatry       Date:  2021-05-16       Impact factor: 2.721

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.